Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.
about
A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapyToxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapyCost-effectiveness of tenofovir instead of zidovudine for use in first-line antiretroviral therapy in settings without virological monitoringIncidence and predictors of first line antiretroviral regimen modification in western KenyaThe Impact of Company-Level ART Provision to a Mining Workforce in South Africa: A Cost-Benefit AnalysisThree-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.When to start antiretroviral therapy in resource-limited settings: a human rights analysis.The cost of providing combined prevention and treatment services, including ART, to female sex workers in Burkina Faso.Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation.Cost of using a patient tracer to reduce loss to follow-up and ascertain patient status in a large antiretroviral therapy program in Johannesburg, South Africa.Cost-effectiveness of antiretroviral regimens in the World Health Organization's treatment guidelines: a South African analysis.cART prescription trends in a prospective HIV cohort in rural Tanzania from 2007 to 2011.Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia.Cost-effectiveness of tenofovir as first-line antiretroviral therapy in India.The cost of providing comprehensive HIV treatment in PEPFAR-supported programs.The determinants of HIV treatment costs in resource limited settings.ART treatment costs and retention in care in Kenya: a cohort study in three rural outpatient clinics.Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa.Economic evaluation of ART in resource-limited countries.Hyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.The state of health economic research in South Africa: a systematic review.NRTI backbone in HIV treatment: will it remain relevant?Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost-Utility Analysis.Five-year trends in treatment changes in an adult cohort of HIV/AIDS patients in Ghana: a retrospective cohort study.Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial.Discovery and Development of Tenofovir Disoproxil Fumarate
P2860
Q28477707-1F645218-9973-414E-B4D1-9D7A58AE5CDDQ28478110-BF189199-29E0-4079-8E6D-3A542F7CBE5DQ28482138-764E323D-AF5D-4F15-878E-85393558A3AFQ28541822-FA220D9E-D7C1-46E6-9BA4-ACEDF893F426Q28608172-864CBA05-FFF0-4C79-8847-2E08496CD59CQ33394513-9E9B42D3-4367-45E9-A9CF-F05C7CA12249Q33548096-6CEE9B09-4352-405A-BBA8-D71C12A662B7Q33783859-806002BE-D4EF-4153-80B3-B1C1D126E29BQ33841718-F35313EC-FB15-444F-B04F-EB97D24F32EDQ34687558-C40BC747-4571-45E4-BFE9-930653A17F56Q34768650-17CD73FC-C823-4308-83EA-5110053A2149Q35098097-D5B69927-DB3B-4759-8FE6-424773DE9132Q35147189-ED929055-12A3-439F-BA77-DC9C6A9E2835Q35217508-42D1FF0E-FCC7-4E32-B92D-983696FBBAD1Q35575721-A37B6D96-7D0B-4B4A-8A6E-8D69FAF459C4Q35576296-696B7AA9-DDB8-434C-AA90-45EEED328B65Q36381028-84445292-4F85-4501-BFA0-EEC6AAEFCD1DQ36508287-99D918A6-CF53-4D58-AE05-579000CB5461Q36749434-A5CEC1B2-8311-4616-AA41-4849E41687E8Q37503832-AD859CE5-8888-4F6E-9518-D0AAE22E7FA4Q37506855-A5B10E05-8269-4F7C-97B4-3DD03359B0E2Q38027235-6EFC8ED7-351B-47F5-A955-2B91A8F09B93Q39533858-FBD2BF4F-9C4B-41B7-AB7C-B418C9099B33Q39675654-93E6E0F2-B9E2-4950-AD6F-3DC18D5601E3Q42152225-8ED703BA-37A2-4A9A-A571-0D2EFDC04C3EQ42234057-ED57C219-64A4-4681-A50E-5B1E0378F25FQ42249729-4C0220C5-B2C4-4910-B14D-0FE63A96A8B2Q45815166-56035090-4BCD-42A8-A7BB-1861385F14B8Q56786248-3163AEEC-1AAF-4CA8-97D4-DEE2F8F2FC5F
P2860
Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@en
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@nl
type
label
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@en
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@nl
prefLabel
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@en
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@nl
P50
P1476
Cost and cost-effectiveness of ...... iral regimens in South Africa.
@en
P2093
Matthew Fox
P304
P356
10.1097/QAI.0B013E31817AE5EF
P407
P577
2008-07-01T00:00:00Z